Phosphodiesterase 4-targeted treatments for autoimmune diseases

Efficacy and safety of apremilast, an oral phosphodiesterase 4 inhibitor, in ankylosing spondylitis

(2012) Ejaz Pathan et al.   ANNALS OF THE RHEUMATIC DISEASES

Oral apremilast in the treatment of active psoriatic arthritis: Results of a multicenter, randomized, double-blind, placebo-controlled study

(2012) Georg Schett et al.   ARTHRITIS AND RHEUMATISM

Efficacy of apremilast in the treatment of moderate to severe psoriasis: a randomised controlled trial

(2012) Kim Papp et al.   LANCET

Disease Progression in MRL/lpr Lupus-Prone Mice Is Reduced by NCS 613, a Specific Cyclic Nucleotide Phosphodiesterase Type 4 (PDE4) Inhibitor

(2012) Thérèse Keravis et al.   PLoS One

Imaging in Axial Spondyloarthritis

(2012) Xenofon Baraliakos et al.   RHEUMATIC DISEASE CLINICS OF NORTH AMERICA

2010 Update of the international ASAS recommendations for the use of anti-TNF agents in patients with axial spondyloarthritis

(2011) D. van der Heijde et al.   ANNALS OF THE RHEUMATIC DISEASES

2010 update of the ASAS/EULAR recommendations for the management of ankylosing spondylitis

(2011) J. Braun et al.   ANNALS OF THE RHEUMATIC DISEASES

Efficacy and Safety of Apremilast in Chronic Cutaneous Sarcoidosis

(2011) Robert P. Baughman   ARCHIVES OF DERMATOLOGY

Focal fat lesions at vertebral corners on magnetic resonance imaging predict the development of new syndesmophytes in ankylosing spondylitis

(2011) Praveena Chiowchanwisawakit et al.   ARTHRITIS AND RHEUMATISM

Disposition, metabolism and mass balance of [14C]apremilast following oral administration

(2011) Matthew Hoffmann et al.   XENOBIOTICA

Ankylosing Spondylitis Disease Activity Score (ASDAS): defining cut-off values for disease activity states and improvement scores

(2010) P. Machado et al.   ANNALS OF THE RHEUMATIC DISEASES

Anti-inflammatory activity of phosphodiesterase (PDE)-IV inhibitors in acute and chronic models of inflammation

(2010) L. SEKUT et al.   CLINICAL AND EXPERIMENTAL IMMUNOLOGY

The flavonoid dioclein reduces the production of pro-inflammatory mediators in vitro by inhibiting PDE4 activity and scavenging reactive oxygen species

(2010) Rodrigo Guabiraba et al.   EUROPEAN JOURNAL OF PHARMACOLOGY

Apoptosis Inhibition Can Be Threatening in Aβ-Induced Neuroinflammation, Through Promoting Cell Proliferation

(2010) A. Abdi et al.   NEUROCHEMICAL RESEARCH

Apremilast, a novel PDE4 inhibitor, inhibits spontaneous production of tumour necrosis factor-alpha from human rheumatoid synovial cells and ameliorates experimental arthritis

(2010) Fiona E McCann et al.   ARTHRITIS RESEARCH & THERAPY

Discovery and structure–activity study of a novel benzoxaborole anti-inflammatory agent (AN2728) for the potential topical treatment of psoriasis and atopic dermatitis

(2009) Tsutomu Akama et al.   BIOORGANIC & MEDICINAL CHEMISTRY LETTERS

The role of the PDE4D cAMP phosphodiesterase in the regulation of glucagon-like peptide-1 release

(2009) WK Ong et al.   BRITISH JOURNAL OF PHARMACOLOGY

Regulation of AMP-activated protein kinase by cAMP in adipocytes: Roles for phosphodiesterases, protein kinase B, protein kinase A, Epac and lipolysis

(2009) Bilal Omar et al.   CELLULAR SIGNALLING

The flavonoid dioclein is a selective inhibitor of cyclic nucleotide phosphodiesterase type 1 (PDE1) and a cGMP-dependent protein kinase (PKG) vasorelaxant in human vascular tissue

(2009) Roberta L. Gonçalves et al.   EUROPEAN JOURNAL OF PHARMACOLOGY

CC-10004 but not thalidomide or lenalidomide inhibits lamina propria mononuclear cell TNF-α and MMP-3 production in patients with inflammatory bowel disease

(2009) J.N. Gordon et al.   Journal of Crohns & Colitis

Discovery of (S)-N-{2-[1-(3-Ethoxy-4-methoxyphenyl)-2-methanesulfonylethyl]-1,3-dioxo-2,3-dihydro-1H-isoindol-4-yl}acetamide (Apremilast), a Potent and Orally Active Phosphodiesterase 4 and Tumor Necrosis Factor-α Inhibitor

(2009) Hon-Wah Man et al.   JOURNAL OF MEDICINAL CHEMISTRY

Roflumilast in symptomatic chronic obstructive pulmonary disease: two randomised clinical trials

(2009) Peter MA Calverley et al.   LANCET

Molecular therapies for systemic lupus erythematosus: clinical trials and future prospects

(2009) Fanny Monneaux et al.   ARTHRITIS RESEARCH & THERAPY

Effects of infliximab on markers of inflammation and bone turnover and associations with bone mineral density in patients with ankylosing spondylitis

(2008) S Visvanathan et al.   ANNALS OF THE RHEUMATIC DISEASES

PDE4 inhibitors: current status

(2008) D Spina   BRITISH JOURNAL OF PHARMACOLOGY

An open-label, single-arm pilot study in patients with severe plaque-type psoriasis treated with an oral anti-inflammatory agent, apremilast

(2008) A. B. Gottlieb et al.   CURRENT MEDICAL RESEARCH AND OPINION

Effect of orally administered KF66490, a phosphodiesterase 4 inhibitor, on dermatitis in mouse models

(2008) Daisuke Harada et al.   INTERNATIONAL IMMUNOPHARMACOLOGY

Curative effects of phosphodiesterase 4 inhibitors cilomilast, roflumilast, and rolipram in dermatitis mouse model

(2008) Daisuke Harada et al.   JOURNAL OF DERMATOLOGICAL SCIENCE

Systemic Lupus Erythematosus

(2008) Anisur Rahman et al.   NEW ENGLAND JOURNAL OF MEDICINE

The relationship between inflammation and new bone formation in patients with ankylosing spondylitis

(2008) Xenofon Baraliakos et al.   ARTHRITIS RESEARCH & THERAPY